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1. Introduction {#jia225375-sec-0005}
===============

Nearly 71 million people worldwide are chronically infected with the hepatitis C virus (HCV) [1](#jia225375-bib-0001){ref-type="ref"}. Owing to overlapping modes of transmission, coinfection with HCV and HIV is frequent. Globally, 2.3 million individuals are estimated to be coinfected with both viruses, with prevalence ranging between 10% and 90%, depending on populations and geographical regions analysed [2](#jia225375-bib-0002){ref-type="ref"}. Despite antiretroviral therapy (ART), HIV‐coinfected individuals present an accelerated course of HCV‐related liver disease compared to HCV‐monoinfected individuals [3](#jia225375-bib-0003){ref-type="ref"}, [4](#jia225375-bib-0004){ref-type="ref"}; immunosuppression and chronic inflammation are some of the causes of such aggravation [5](#jia225375-bib-0005){ref-type="ref"}. Additionally, among HIV/HCV‐coinfected individuals, some subjects progress to cirrhosis and others do not develop any degree of liver fibrosis in their life time. Factors involved in such heterogeneity remain unidentified.

In humans, natural killer (NK) cells represent approximately 10% of peripheral blood mononuclear cells, but up to 30% to 50% of intrahepatic lymphoid cells [6](#jia225375-bib-0006){ref-type="ref"}. As effectors of the innate immune system, NK cells target virally infected or transformed cells by mediating cytotoxicity and producing proinflammatory cytokines. Additionally, cumulative evidence has revealed that NK cells play an important role in inhibiting hepatic fibrosis [7](#jia225375-bib-0007){ref-type="ref"}. Due to chronic hepatic injury, hepatic stellate cells (HSCs) are activated, which leads to extracellular matrix deposition, fibrosis and eventually, cirrhosis. Independent studies in both preclinical and clinical models have reported that NK cells kill early activated or senescence‐activated HSCs by releasing cytotoxic granules or inducing death signals through the expression of death receptors [8](#jia225375-bib-0008){ref-type="ref"}, [9](#jia225375-bib-0009){ref-type="ref"}, [10](#jia225375-bib-0010){ref-type="ref"}, [11](#jia225375-bib-0011){ref-type="ref"}, [12](#jia225375-bib-0012){ref-type="ref"}, [13](#jia225375-bib-0013){ref-type="ref"}, [14](#jia225375-bib-0014){ref-type="ref"}. Secreted‐IFN‐γ also enhances antifibrotic effect of NK cells by inducing HSCs cycle arrest and apoptosis [15](#jia225375-bib-0015){ref-type="ref"}. Conversely, it has been suggested that HSCs are capable of impairing NK cell antifibrotic capacity [16](#jia225375-bib-0016){ref-type="ref"}, [17](#jia225375-bib-0017){ref-type="ref"}.

Chronic HCV and HIV infections leave a distinct signature on peripheral blood NK cells [18](#jia225375-bib-0018){ref-type="ref"}, [19](#jia225375-bib-0019){ref-type="ref"}, and so, alterations of NK cell phenotype and/or function were suggested as sensitive biomarkers of viral exposure. To date, whether progression of hepatic fibrosis in coinfected individuals is associated to a defective NK function has not been demonstrated. In a previous study, we described that HIV/HCV‐coinfected individuals with advanced fibrosis presented lower percentages of CD4^+^ T‐cells and NK cells compared with subjects with minimal fibrosis [20](#jia225375-bib-0020){ref-type="ref"}. Here, we show for the first time that progression of liver fibrosis is associated to a defective NK cell function that could not be attributed to a defective modulation by CD4^+^ T‐cells.

2. Methods {#jia225375-sec-0006}
==========

Healthy volunteers (HV, n = 20) and HIV/HCV‐coinfected individuals (n = 34) on follow‐up at a Public Hospital Infectious Diseases Unit, Buenos Aires, Argentina, were included in this study. Written Informed Consent was obtained. Blood samples were withdrawn at INBIRS Institute. The study was conducted in accordance with the Declaration of Helsinki, and was approved by the Bioethics Committee of Fundación Huésped. Sample collection and processing were performed from July 2016 to July 2018.

HIV/HCV‐coinfected individuals were classified based on their level of fibrosis according to transient hepatic elastography (FibroScan^®^ and SuperSonic Imagine\'s Aixplorer^®^). Subjects with a result of ≤7.1 Kpa were classified as compatible with a METAVIR score of F0/F1: absent or minimal fibrosis and those with ≥12.5 Kpa as compatible with METAVIR F4: cirrhosis [21](#jia225375-bib-0021){ref-type="ref"}, [22](#jia225375-bib-0022){ref-type="ref"}, [23](#jia225375-bib-0023){ref-type="ref"}. Individuals enrolled in this study were not acutely or chronically HBV‐infected (determined by serology); and denied current use of recreational drugs and more than 14 units/week of alcohol intake on a regular basis. HV were recruited among hospital employees. To be included they had to present a value of ≤5 Kpa on transient hepatic elastography, had negative HIV/HCV/HBV serology, no history of alcohol, illicit drug consumption and other clinically relevant conditions.

2.1. Isolation of PBMC, NK and CD4^+^ T‐cells {#jia225375-sec-0007}
---------------------------------------------

See Supporting Information.

2.2. Activation of CD4^+^ T‐cells {#jia225375-sec-0008}
---------------------------------

For CD4^+^ T‐cell activation, 100,000 freshly isolated CD4^+^ T‐cells were incubated with Dynabeads Human T‐Activator CD3/CD28 (Thermo Fisher, USA) at different bead‐to‐cell ratios, for different times. Then, cells were processed by flow cytometry to determine CD69, CD25 and CD38 expression. Conditioned medium from activated CD4^+^ T‐cells (CM) were collected, and stored at −80°C.

For NK cytokine secretion assays, CM from CD4^+^ T‐cells of a selected HV was used. Selection of healthy CD4^+^ T‐cells was performed after certifying that activation was efficiently induced by anti‐CD3/CD28 beads (Figure [S1](#jia225375-sup-0001){ref-type="supplementary-material"}A). To obtain adequate amounts of material, supernatants from activated (bead‐to‐cell ratio of 1:1, 48 hours) CD4^+^ T‐cells of the selected donor were obtained on two different occasions, and subsequently pooled.

2.3. Cytokine secretion {#jia225375-sec-0009}
-----------------------

See Supporting Information.

2.4. CD107a assay {#jia225375-sec-0010}
-----------------

For NK cell degranulation assays, the K562 cell line was used as a sensible target at an effector to target ratio of 1:1. PBMC were thawed and cultured overnight in cRPMI, at 37°C with 5% CO2. Next, one million viable PBMC were coincubated for five hours with K562 cells, in the presence of anti‐CD107a‐FITCmAb, brefeldin and monensin (4 μL, 10 μg/mL and 0.7 μg/mL respectively, BD Biosciences, San Diego, CA, USA). To assess the basal levels of degranulation, PBMC were incubated in the absence of K562 cells.

Afterwards, we evaluated the effect of CM from CD4^+^ T‐cells of HIV/HCV‐coinfected individuals on healthy NK cells. To avoid inter‐subject bias, NK cells purified from a single HV were used as effector. Selection of healthy NK cells was performed after certifying that degranulation capacity was efficiently induced by K562 cells (Figure [S1](#jia225375-sup-0001){ref-type="supplementary-material"}B). Isolated NK cells were pretreated for 18 hours with CM from activated CD4^+^ T‐cells. Then, 100,000 viable NK cells were exposed to either K562 cells or cRPMI, as formerly described.

2.5. IFN‐γ and TNF‐α secretion {#jia225375-sec-0011}
------------------------------

For cytokine secretion assays, either PBMC or purified NK cells were used. PBMC from HCV/HIV‐coinfected individuals were pretreated with either cRPMI or CM from activated CD4^+^ T‐cells from a selected HV. On the one hand, NK cells from a single volunteer were pretreated with CM from HIV/HCV‐coinfected individuals. After 18 hours, cells were coincubated with the K562 cell line, as described in the previous section.

2.6. Flow cytometric analysis {#jia225375-sec-0012}
-----------------------------

Cells were immunophenotyped by flow cytometry on a FACS Canto Flow Cytometer (BD Biosciences). For antibodies and gating strategies, see Table [S1](#jia225375-sup-0004){ref-type="supplementary-material"}, Figure [S2](#jia225375-sup-0002){ref-type="supplementary-material"}. Flow cytometry data were analysed by FlowJo software v.10 (FlowJo Enterprise, Treestar Inc., Ashland, OR, USA). Phenotype and functionality assays were performed according to cells availability.

2.7. Statistical analysis {#jia225375-sec-0013}
-------------------------

Statistical analyses were performed using GraphPad Prism v.7.0 (GraphPad Software Inc., San Diego, CA, USA) and SPSS software v.19.0 (SPSS Corp., Armonk, NY, USA). Parametric and non‐parametric tests were used as appropriate, for details; see Supporting Information. Significance was assumed at *p *\<* *0.05. (\*) *p* \< 0.05, (\*\*) *p* \< 0.01 and (\*\*\*) *p* \< 0.001.

3. Results {#jia225375-sec-0014}
==========

3.1. Frequency of NK and CD4^+^ T‐cells is severely diminished in HIV/HCV‐coinfected individuals with advanced fibrosis {#jia225375-sec-0015}
-----------------------------------------------------------------------------------------------------------------------

This study enrolled HIV/HCV‐coinfected individuals with minimal or advanced fibrosis. All HIV‐coinfected individuals were on ART with undetectable HIV viral load, with no difference in the time on ART between groups. One third of the individuals in the advanced fibrosis group and 14% with minimal fibrosis received IFN‐based HCV treatment, with a median of eight years (IQR eight to eleven years) before sampling, and none of them achieve sustained virologic response. Age, time of known HIV or HCV infection, and HCV genotypes were similar between individuals (Table [1](#jia225375-tbl-0001){ref-type="table"}). As expected, F4 group was positively associated to liver stiffness, AST, γ‐GT, and total bilirubin levels; and negatively to platelet count, albumin levels and prothrombin time (Table [1](#jia225375-tbl-0001){ref-type="table"}). Male sex has been shown to be positively related with liver fibrosis progression in HCV‐monoinfected or HIV/HCV‐coinfected individuals [24](#jia225375-bib-0024){ref-type="ref"}, [25](#jia225375-bib-0025){ref-type="ref"}. Nevertheless, neither NK nor CD4^+^ T‐cell frequencies were associated with gender in our study.

###### 

Subjects characteristics

  Characteristics                                                            Control, n = 20                                                F0/F1, n = 16                                           F4, n = 18                                                   *p* value
  -------------------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------ -----------
  Age (years)[a](#jia225375-note-0002){ref-type="fn"}                        44.4 (26 to 70)                                                47.1 (23 to 57)                                         51.2 (35 to 64)                                              0.20
  Female sex (%)[b](#jia225375-note-0002){ref-type="fn"}                     9 (45)                                                         7 (44)                                                  4 (22)                                                       0.12
  Prior IDU (%)                                                              ‐                                                              11 (69)                                                 15 (82)                                                      0.42
  CD4 count (cells/μL)[a](#jia225375-note-0002){ref-type="fn"}               1126.0 (629 to 2037)[c](#jia225375-note-0002){ref-type="fn"}   716.6 (153 to 1412)                                     563.8 (54 to 1278)[c](#jia225375-note-0002){ref-type="fn"}   0.002
  CD8 count (cells/μL)[a](#jia225375-note-0002){ref-type="fn"}               722.4 (348 to 1566)                                            877.1 (321 to 1812)                                     947.8 (253 to 2230)                                          0.73
  Known Time HCV infection (years)[a](#jia225375-note-0002){ref-type="fn"}   ‐                                                              16.0 (1 to 25)                                          16.3 (3 to 31)                                               0.67
  Known time HIV infection (years)[a](#jia225375-note-0002){ref-type="fn"}   ‐                                                              19.9 (9 to 31)                                          19.3 (3 to 30)                                               0.80
  Time of ART (years)[a](#jia225375-note-0002){ref-type="fn"}                ‐                                                              12.4 (7 to 17)                                          13.6 (8 to 20)                                               0.60
  Previous use of ddI/d4T                                                    ‐                                                              3 (20)                                                  4 (25)                                                       \>0.99
  Present ART based on PI                                                    ‐                                                              7 (46)                                                  7 (38)                                                       \>0.99
  Present ART based on NNRTI                                                 ‐                                                              5 (31)                                                  2 (12)                                                       0.21
  Present ART based on INSTI                                                 ‐                                                              4 (23)                                                  9 (50)                                                       0.17
  Previous IFN/PEGIFN                                                        ‐                                                              3 (14)                                                  6 (33)                                                       0.44
  HCV genotype (%)[a](#jia225375-note-0002){ref-type="fn"}                                                                                                                                                                                                       
  Genotype 1a                                                                ‐                                                              14 (87.5)                                               14 (77.7)                                                    0.60
  Genotype 1b                                                                ‐                                                              2 (12.5)                                                1 (5.55)                                                     
  Genotype 3a                                                                ‐                                                              ‐                                                       2 (11.11)                                                    
  Genotype 4                                                                 ‐                                                              ‐                                                       1 (5.55)                                                     
  HCV viral load (log~10~ copies)[a](#jia225375-note-0002){ref-type="fn"}    ‐                                                              6.12 (3.14 to 7.54)                                     6.12 (4.74 to 7.38)                                          0.97
  Liver stiffness (Kpa)[a](#jia225375-note-0002){ref-type="fn"}              4.50 (4 to 5)                                                  6.02 (4 to 8)[d](#jia225375-note-0002){ref-type="fn"}   20.5 (12 to 36)[d](#jia225375-note-0002){ref-type="fn"}      0.008
  APRI score                                                                 nd                                                             0.57 (0.25 to 1.34)                                     2.05 (0.42 to 11.6)                                          0.04
  ALT (IU/L)[a](#jia225375-note-0002){ref-type="fn"}                         nd                                                             64.3 (25 to 122)                                        90.9 (25 to 190)                                             0.09
  AST (IU/L)[a](#jia225375-note-0002){ref-type="fn"}                         nd                                                             50.6 (25 to 95)                                         94.1 (37 to 209)                                             0.007
  γ‐GT (IU/L)[a](#jia225375-note-0002){ref-type="fn"}                        nd                                                             118.9 (31 to 252)                                       185.9 (72 to 372)                                            0.06
  Albumin (g/dL)[a](#jia225375-note-0002){ref-type="fn"}                     nd                                                             4.33 (3.9 to 5.1)                                       4.07 (3.1 to 4.6)                                            0.09
  Platelets (×10^3^/mm^3^)[a](#jia225375-note-0002){ref-type="fn"}           nd                                                             200.0 (136 to 258)                                      141.2 (25 to 255)                                            0.003
  Total bilirubin (μg/dL)[a](#jia225375-note-0002){ref-type="fn"}            nd                                                             0.59 (0.2 to 1.6)                                       1.30 (0.5 to 2.5)                                            0.0003
  Prothrombin time (%)[a](#jia225375-note-0002){ref-type="fn"}               nd                                                             96.3 (84.8 to 100)                                      82.4 (50.9 to 100)                                           0.007

Time of known HIV/HCV infection is defined as the time from first HIV/HCV diagnosis by serology. ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate transaminase; d4T, stavudine; ddI, didanosine; IDU, intravenous drug user; IFN/PEGIFN, interferon/pegilated interferon; INSTI, integrase strand transfer inhibitor; nd, not determined; NNRTI, non‐nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; γ‐GT, gamma‐glutamyl transpeptidase.

^a^Mean (range); ^b^number of cases (number/total in %); ^c^ *p*=0.0005 control vs. F4; ^d^ *p*\<0.0001 F0/F1 versus F4, ANOVA followed by Tukey′s test.

John Wiley & Sons, Ltd

In this new group of HIV/HCV‐coinfected individuals, we confirmed our previous observations [20](#jia225375-bib-0020){ref-type="ref"} showing that advanced fibrosis subjects displayed the lowest CD4^+^ T‐cell and NK cell frequencies (Table [2](#jia225375-tbl-0002){ref-type="table"}). Furthermore, we observed that advanced fibrosis subjects displayed lower frequencies of CD56^dim^ but increased percentage of CD56^bright^ cells than HV, and individuals with minimal fibrosis.

###### 

Frequencies of peripheral blood lymphocyte populations in healthy volunteers and HIV/HCV‐coinfected individuals

  Characteristics                                              Control                  F0/F1                    F4                      *p* value
  ------------------------------------------------------------ ------------------------ ------------------------ ----------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  CD4^+^ T‐cells (%)[a](#jia225375-note-0004){ref-type="fn"}   43.07 (30.00 to 60.00)   32.80 (18.00 to 46.00)   23.53 (9.00 to 34.00)   0.033[b](#jia225375-note-0004){ref-type="fn"}, 0.0001[c](#jia225375-note-0004){ref-type="fn"}, 0.037[d](#jia225375-note-0004){ref-type="fn"}
  NK cells (%)[a](#jia225375-note-0004){ref-type="fn"}         9.63 (4.03 to 17.35)     8.34 (3.13 to 14.40)     4.16 (1.29 to 10.11)    0.0004[c](#jia225375-note-0004){ref-type="fn"}, 0.003[d](#jia225375-note-0004){ref-type="fn"}
  CD56 dim                                                     96.56 (92.8 to 99.1)     97.46 (93.5 to 99.2)     87.95 (64.4 to 99.2)    0.01[c](#jia225375-note-0004){ref-type="fn"}, 0.007[d](#jia225375-note-0004){ref-type="fn"}
  CD56 bright                                                  3.44 (0.87 to 7.18)      2.54 (0.73 to 6.50)      12.05 (1.27 to 35.56)   0.01[c](#jia225375-note-0004){ref-type="fn"}, 0.007[d](#jia225375-note-0004){ref-type="fn"}

NK, natural killer.

^a^Mean (range); ^b^control vs. F0/F1, ^c^control vs. F4, ^d^F0/F1 versus F4.

John Wiley & Sons, Ltd

3.2. Functionality of NK cells is compromised in individuals with advanced liver fibrosis {#jia225375-sec-0016}
-----------------------------------------------------------------------------------------

First, functionality of NK cells from HV, as well as HIV/HCV‐coinfected individuals was analysed. To evaluate NK cell degranulation, we analysed the expression of cell surface CD107a, as a measure of NK cell degranulation [26](#jia225375-bib-0026){ref-type="ref"}. Interestingly, basal (unstimulated) expression of CD107a differed between groups, with the highest percentage of CD107a^+^ NK cells corresponding to F4 individuals (Figure [1](#jia225375-fig-0001){ref-type="fig"}A, left panel). However, after K562 coincubation, CD107a expression on NK cells reached similar levels in HIV/HCV‐coinfected individuals and HV (Figure [1](#jia225375-fig-0001){ref-type="fig"}A, middle panel), suggesting an impaired ability of NK cells from F4 individuals to be activated *ex vivo*. In fact, the degranulation response (fold change) induced upon incubation of NK cells with K562 cells was significantly lower in F4 individuals compared with the other two groups (Figure [1](#jia225375-fig-0001){ref-type="fig"}A, right panel). Interestingly, when F4 individuals were analysed, the frequency of NK cells negatively correlated with basal percentages of CD107a^+^ NK cells (Spearman rho = −0.70, *p* = 0.0007), and positively, with the increased degranulation response induced by K562 cells (Spearman rho = 0.71, *p* = 0.0006) (Figure [1](#jia225375-fig-0001){ref-type="fig"}B).

![NK cell phenotype and functionality in HIV/HCV‐coinfected individuals with minimal or advanced liver fibrosis\
(**A**) CD107a externalization in PBMC from control and HIV/HCV‐coinfected individuals with METAVIR F0/F1 or F4 scores incubated with cRPMI (basal) or K562 cells (+K562). (**B**) Correlation between frequency of NK cells and degranulation capacity in F4 individuals. (**C** and **D**) For IFN‐γ and TNF‐α expression, NK cells were pretreated with conditioned medium (CM) from CD4+ T lymphocytes or cRPMI, and subsequently exposed to K562 cells. (**E**) PBMCs were stained for CD25, CD69, NKp46, NKG2D and PD‐1 markers. Individual NK cell frequencies, median and 25th and 75th percentiles are indicated. Statistical comparisons were performed using Kruskal‐Wallis followed by Dunn′s multiple‐comparison tests (**A** and **D**) and Mann‐Whitney test (**E**). NK, natural killer.](JIA2-22-e25375-g001){#jia225375-fig-0001}

Then, we analysed the pattern of cytokine secretion by NK cells. In order to resemble physiologic activation of NK cells by CD4^+^ T lymphocytes, cytokine secretion by NK cells from both healthy and coinfected individuals was stimulated upon pre‐incubation with CM obtained from CD4^+^ T‐cells activated by anti‐CD3/CD28 coated beads, as described in Figure [1](#jia225375-fig-0001){ref-type="fig"}C. Control experiments performed with a HV showed that this treatment effectively activated CD4^+^ T‐cells, increasing the expression of CD69 and the production of a number of cytokines, and also that incubation of NK cells with the CM obtained from activated CD4^+^ T‐cells efficiently activated NK cells, as indicated by the increased expression of CD107a (Figure [S1](#jia225375-sup-0001){ref-type="supplementary-material"}). We next analysed the production of IFN‐γ and TNF‐α by NK cells from all the enrolled groups after incubation with CMs obtained from activated CD4^+^ T‐cells isolated from a HV. In the absence of CM pretreatment, exposure to K562 cells induced low levels of cytokine secretion. While production of IFN‐γ did not differ among groups, TNF‐α secretion was greatly impaired in subjects with advanced fibrosis (Figure [1](#jia225375-fig-0001){ref-type="fig"}D). In CM pretreated NK cells, the frequency of IFN‐γ^+^ or TNF‐α^+^ cells was significantly lower in F4 individuals compared with healthy and F0/F1 individuals.

Due to small NK cell frequencies displayed by individuals with advanced fibrosis, effector functions of CD56^dim^ and CD56^bright^ populations could not be studied in all recruited subjects. When analysing degranulation and both IFN‐γ and TNF‐α secretion on CD56^dim^ population; we found similar results as the obtained with total NK cells. Regarding CD56^bright^ cells, while CD107a expression was not significantly affected (Figure [S3](#jia225375-sup-0003){ref-type="supplementary-material"}A), there is a tendency towards a reduction in cytokine production in METAVIR F4 subjects (Figure [S3](#jia225375-sup-0003){ref-type="supplementary-material"}B,C).

To further characterize NK cell populations in HIV/HCV‐coinfected subjects, the expression of the activation markers CD25 and CD69, the activating receptors NKp46 and NKG2D, and PD‐1, a marker of cellular exhaustion, were assessed on recently thawed PBMC (Figure [1](#jia225375-fig-0001){ref-type="fig"}E). While the expression of PD‐1 on NK cells was significantly higher in individuals with F4 scores, the other surface markers were not differentially expressed in HIV/HCV‐coinfected individuals. Similar results were obtained analysing both the percentages of NK cells expressing each marker (Figure [1](#jia225375-fig-0001){ref-type="fig"}E) and the median fluorescent intensity (MFI) for each of the markers analysed (not shown). Neither functional nor phenotypical differences were found in NK cells according gender (Table [S2](#jia225375-sup-0004){ref-type="supplementary-material"}).

3.3. Activation of CD4^+^ T‐cells is similarly induced in HIV/HCV‐coinfected individuals with different stages of hepatic fibrosis {#jia225375-sec-0017}
----------------------------------------------------------------------------------------------------------------------------------

Next, activation of CD4^+^ T‐cells from HIV/HCV‐coinfected individuals was studied. Isolated CD4^+^ T‐cells were stimulated with anti‐CD3/CD28 beads and frequencies of CD4^+^/CD69^+^, CD4^+^/CD25^+^ and CD4^+^/CD38^+^ cells were measured. After 48 hours of stimulation at a bead‐to‐cell ratio of 1:1, frequency of CD4^+^/CD25^+^, CD4^+^/CD69^+^ and CD4^+^/CD38^+^ T‐cells were increased in a similar way in both METAVIR F0/F1 and F4 individuals (Figure [2](#jia225375-fig-0002){ref-type="fig"}A). Further experiments were performed using a shorter incubation period and different bead‐to‐cell ratios in order to reveal potential differences between the two groups. No differences were observed between HIV and HCV‐coinfected individuals with minimal or advanced liver fibrosis in terms of frequency of activated CD4^+^ T‐cells (Figure [2](#jia225375-fig-0002){ref-type="fig"}B). Similar results were obtained analysing MFI (not shown). Additionally, IL‐2 levels in CD4^+^ T‐cell CM were evaluated by ELISA. In line with the previous results, there were no significant differences between the groups regarding IL‐2 secretion at any tested condition (Figure [3](#jia225375-fig-0003){ref-type="fig"}A). Also, CD4^+^ T‐cell activation did not vary between male and female subjects (Table [S2](#jia225375-sup-0004){ref-type="supplementary-material"}). We conclude that there are no differences in the activation pattern of CD4^+^ T‐cells obtained from individuals with minimal or advanced fibrosis.

![Activation of CD4+ T‐cells from HIV/HCV‐coinfected individuals with minimal or advanced liver fibrosis\
(**A**) CD69, CD25 and CD38 expression were measured on CD4+ T‐cells from HIV/HCV‐coinfected subjects with METAVIR F0/F1 or F4 scores after 48 hours of vehicle (basal) or anti‐CD3/CD28 stimulation (bead‐to‐cell ratio of 1:1). (**B**) The same markers were determined after anti‐CD3/CD28 stimulation (1:5 or 1:35 ratios; 24 hours). Individual CD4+ T‐cell frequencies, median and 25th and 75th percentiles are indicated. Statistical comparisons were performed using Wilcoxon matched paired test (**A**) and Mann‐Whitney test (**B**).](JIA2-22-e25375-g002){#jia225375-fig-0002}

![*Ex vivo* effect of CD4+ T‐cells from HIV/HCV‐coinfected individuals with minimal or advanced liver fibrosis on NK cells\
(**A**) IL‐2 levels in CM. (**B**) Conditioned medium (CM) from activated CD4+ T‐cells from HIV/HCV‐coinfected subjects with METAVIR F0/F1 or F4 scores were collected, and subsequently used for pretreatment of NK cells from one healthy individual. Finally, NK cells were coincubated with K562 cells. **(C)** CD107a, IFN‐γ and TNF‐α expression on NK cells. Individual CD4+ T‐cell frequencies, median and 25th and 75th percentiles are indicated. Statistical comparisons were performed using Mann‐Whitney test. NK, natural killer.](JIA2-22-e25375-g003){#jia225375-fig-0003}

3.4. NK cell functionality is similarly modulated by CD4^+^ T‐cells purified from individuals with minimal or advanced fibrosis {#jia225375-sec-0018}
-------------------------------------------------------------------------------------------------------------------------------

Finally, *ex vivo* stimulation of NK cells by cytokines from activated CD4^+^ T‐cells of HIV/HCV‐coinfected individuals was evaluated. NK cells from a selected HV were pretreated with CM from activated CD4^+^ T‐cells (Figure [3](#jia225375-fig-0003){ref-type="fig"}B). Subsequently, NK cells were coincubated with K562 cells, and CD107a externalization, as well as cytokine production was measured. As shown in Figure [3](#jia225375-fig-0003){ref-type="fig"}C, induction of NK cell degranulation progressively decreased, as cells were pre‐incubated with CM from CD4^+^ T‐cells stimulated with increasing cell‐to‐anti‐CD3/CD28 bead ratios, probably reflecting a decline in cytokine concentration, for example, IL‐2 (Figure [3](#jia225375-fig-0003){ref-type="fig"}A), in CD4^+^ T‐cell CM. However, no significant differences regarding CD107a expression on healthy NK cells were registered after treatment with CM from CD4^+^ T‐cells of F0/F1 or F4 individuals, at any tested condition. Cytokine secretion was similarly upregulated regardless of the strength of CD4^+^ T‐cell activation. In line with the previous degranulation results, fibrosis status of individuals was not differentially associated to either IFN‐γ or TNF‐α production by NK cells. MFI evaluation of degranulation and cytokine secretion yielded similar results (not shown).

In summary, we did not observe differences in the capacity of CD4^+^ T‐cells from individuals with minimal or advanced fibrosis, to modulate neither NK cell degranulation or IFN‐γ and TNF‐α secretion.

4. Discussion {#jia225375-sec-0019}
=============

Progression of liver disease in HCV‐monoinfected and HIV/HCV‐coinfected individuals is extremely variable. In our patient cohort, HIV/HCV‐coinfected individuals had similar time of known HIV and HCV infection and ART, however, some of them progressed to cirrhosis whereas others had minimal liver fibrosis. NK cells have shown to play an important role in the immune response against HCV infection and in the modulation of liver fibrosis development. It was previously reported in HCV monoinfection and HIV/HCV coinfection that peripheral NK cell frequency is significantly decreased [27](#jia225375-bib-0027){ref-type="ref"}, [28](#jia225375-bib-0028){ref-type="ref"}, [29](#jia225375-bib-0029){ref-type="ref"}. Recently, we showed that among HIV/HCV‐coinfected subjects, advanced fibrosis was associated to the lowest frequencies of circulating NK cells [20](#jia225375-bib-0020){ref-type="ref"}. Although it has been suggested that NK cells were preferentially localized in liver tissue during viral chronic infections [30](#jia225375-bib-0030){ref-type="ref"}, mechanisms for decreased peripheral NK cell frequencies in individuals with advanced fibrosis are not fully understood. In the present study, we report that the compartment of NK cells in patients with advanced fibrosis shows not only a quantitative defect but also a compromise in cell functionality.

In this study, we show that *ex vivo* degranulation of NK cells from cirrhotic individuals coinfected with HIV and HCV is poorly induced by K562 cells, perhaps reflecting an exhausted phenotype. Augmented levels of basal degranulation were described in antiretroviral‐treated HIV‐positive individuals [31](#jia225375-bib-0031){ref-type="ref"}, possibly indicating the presence of targets for NK cell‐mediated natural cytotoxicity in the course of infection. HCV‐associated immune response, and also both hepatic and systemic proinflammatory milieu may contribute to this phenomenon. Interestingly, here we show that cirrhotic patients with the lowest NK cell frequencies displayed the greatest percentages of basal CD107a+ NK cells, and the weakest induction of NK cell degranulation by K562 cells. This observation indicates that the frequency and function of NK cells could be related, although the mechanisms underlying this association remain to be defined. Our results suggest that in HIV/HCV‐coinfected individuals, liver damage may lead to *in vivo* over‐activation and functional exhaustion (i.e. the impossibility to exhibit a significant degranulation upon exposure to susceptible targets) of peripheral NK cell subset.

Regarding cytokine secretion, we show that IFN‐γ and TNF‐α production by NK cells is significantly impaired in individuals with advanced fibrosis. In particular, our results may indicate that NK cells from F4 individuals failed at responding to CD4^+^ T‐cell derived stimuli. Nevertheless, since NK cells were studied in PBMC fractions, interaction with other immune cells and their products may have influenced the observed results. It is evident that experimental settings, for example, cytokine prestimulation of NK cells, evaluation of spontaneous degranulation, and interaction with other immune cells are critical when analysing *ex vivo* NK cell cytotoxicity. Together, our results are consistent with those reporting impaired functionality of NK cells during HCV monoinfection [32](#jia225375-bib-0032){ref-type="ref"}, [33](#jia225375-bib-0033){ref-type="ref"}, [34](#jia225375-bib-0034){ref-type="ref"}, [35](#jia225375-bib-0035){ref-type="ref"}, [36](#jia225375-bib-0036){ref-type="ref"}, and also HIV/HCV coinfection [29](#jia225375-bib-0029){ref-type="ref"}. However, they could be also interpreted in the context of a functional NK cell dichotomy, where NK cells display a decreased production of antiviral cytokines but an enhanced basal cytotoxicity, which is impaired when these cells are exposed to their targets [18](#jia225375-bib-0018){ref-type="ref"}, [37](#jia225375-bib-0037){ref-type="ref"}. Cytokine secretion and cytotoxicity can be uncoupled when NK cells contact their target cells [38](#jia225375-bib-0038){ref-type="ref"}.

Possible mechanisms underlying a compromised NK cell function in the course of HCV infection have been related to changes in the activation state and/or an imbalanced NK cell receptor expression [39](#jia225375-bib-0039){ref-type="ref"}. Here, we evaluated CD69, CD25, NKp46 and NKp30 cell markers but only PD‐1 expression was associated to liver fibrosis progression. In line with the results from functional assays, PD‐1 expression may be reflecting an exhausted NK pool in individuals with advanced liver fibrosis. Although PD‐1 expression in NK cells was already linked to chronic HCV infection [40](#jia225375-bib-0040){ref-type="ref"}, to the best of our knowledge, no relationship between advanced liver fibrosis and the PD‐1/PDL‐1 axis in NK cells has been previously addressed. Further studies are required to analyse the utility of PD‐1 as a marker of fibrosis progression as well as to explore whether PD‐1 could represent a potential immune check point for targeted therapies aimed to modulate liver fibrosis.

Despite all individuals were on successful ART therapy, F4 individuals have lower CD4^+^ T‐cell counts and percentages than subjects with minimal fibrosis. Studies of liver fibrosis progression in HIV seronegative individuals have proposed that low absolute CD4^+^ T‐cell counts may be attributable to advanced liver disease, due to hypersplenism secondary to portal hypertension, and consequently, leucopenia [41](#jia225375-bib-0041){ref-type="ref"}, [42](#jia225375-bib-0042){ref-type="ref"}, [43](#jia225375-bib-0043){ref-type="ref"}. Nevertheless, hypersplenism could not be associated with the decrease in the percentage CD4^+^ T‐cell observed in our group of cirrhotic individuals (since leucopenia affects the absolute number of the different leucocytes but not the proportion of them). Therefore, our results suggest that the lower frequency of these cells could be associated with the progression to liver fibrosis rather than being a consequence of end stage liver disease. It is well known that CD4^+^ T‐cells boost NK cell activation via IL‐2 secretion [44](#jia225375-bib-0044){ref-type="ref"} and recently, impaired CD4^+^ T‐cell stimulation of NK cells has been linked to liver fibrosis by comparing HV and HIV/HCV‐coinfected individuals, [45](#jia225375-bib-0045){ref-type="ref"}. Our present observations differ from this study in two ways. First, we did not analyse coinfected subjects as a unique population, but rather we stratified coinfected individuals according to their degree of fibrosis, enabling us to define associations between the degree of fibrosis and the phenotype and function of NK cells. Second, we observed that the response to activation stimuli of CD4^+^ T‐cells in coinfected subjects as well as their ability to modulate the function of NK cells did not differ between individuals with minimal and maximal degree of fibrosis. It has been reported that HIV/HCV‐coinfected subjects with higher chances to develop liver fibrosis are those with lower CD4^+^ T‐cell recovery after HIV treatment [46](#jia225375-bib-0046){ref-type="ref"}. In view of our results, CD4^+^ T‐cell count might contribute more significantly to fibrosis progression than a deficient CD4^+^ T‐cell modulation capacity.

Our study has some limitations. First, a larger sample size would permit stronger associations between variables, and especially to robustly address NK CD56^bright^ population. Also, it would be very interesting to study CD56^neg^ NK cells, since they are described as an aberrant and hypo functional cell subset found at elevated levels in individuals chronically infected with HIV‐1 and HCV [47](#jia225375-bib-0047){ref-type="ref"}. Finally, although the main focus of our study was to determine whether CD4^+^ T‐cells from coinfected individuals with minimal or advanced fibrosis had different capacity to stimulate NK cells, we cannot rule out that a defect in the function of HIV‐ or HCV‐specific CD4^+^ T‐cells might contribute to NK cell dysfunction in coinfected subjects. It would be very interesting to investigate the potential role of HIV‐ or HCV‐specific CD4^+^ T‐cells to modulate liver fibrosis.

5. Conclusions {#jia225375-sec-0020}
==============

Association between NK cell phenotype and function and the outcome of acute HCV infection was extensively reported [48](#jia225375-bib-0048){ref-type="ref"}, [49](#jia225375-bib-0049){ref-type="ref"}, [50](#jia225375-bib-0050){ref-type="ref"}, nevertheless, it remains unclear whether phenotypical and/or functional characteristics of NK cells are actually determinants for the rate of liver fibrosis progression. We and others have previously shown an association between low NK and CD4^+^ T‐cell counts with advanced liver fibrosis in HIV/HCV‐coinfected individuals [20](#jia225375-bib-0020){ref-type="ref"}, [29](#jia225375-bib-0029){ref-type="ref"}. Here, we provide further support for this phenomenon, and also demonstrate that NK functionality is significantly impaired in coinfected individuals with advanced fibrosis. Although the underlying mechanisms remain to be defined, our results suggest they could not be attributed to an inefficient modulation of NK cell function by CD4^+^ T‐cells. In sum, lower CD4^+^ T and NK cells, as well as a decreased NK functionality may represent *ex vivo* biological markers of advanced liver disease.
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###### 

**Figure S1.** Lymphocytes isolated from a selected healthy volunteer. NK and CD4^+^ T‐cells were purified from PBMC of a 42‐year‐old woman, HIV/HCV/HBV negative, with no history of alcohol consumption, tabaquism or ilicit drug use, thyroid or celiac disease, and no other clinically relevant conditions. % NK cells: 8.62, CD4^+^ T‐cell count: 754, % CD4^+^ T‐cells: 38. (**A**) CD4^+^ T‐cells were stimulated with anti‐CD3/CD28 beads in different bead‐to‐cell ratios (1:1, 48 hours; others 24 hours), and percentages of CD69+/CD4^+^ T cells were monitored. IL‐2 levels were also measured in corresponding culture supernatants. Right: Additional cytokines were quantified in CD4^+^ T‐cell CM (1:1, 48 hours). (**B**) CD107a externalization in CM‐prestimulated PBMC, co‐cultured with K562 cells (CM+K562). As control, cRPMI‐prestimulated PBMC were either exposed to K562 cells (+K562) or cRPMI (basal). Determinations were performed in duplicate. Data are presented as mean ± SD. Statistical comparisons were performed using Wilcoxon matched paired test. nd, not detected.

###### 

Click here for additional data file.

###### 

**Figure S2.** Gating strategy, and representative dot plots for flow cytometry analysis. (**A**) NK cell subset was defined as CD3‐/CD56+ viable lymphocytes. (**B**) Upon incubation with cRPMI (basal) or K562 cells (+K562), CD107a+ NK cells were determined (Top). Intracellular IFN‐γ and TNF‐α expression was measured in cRPMI or CM‐prestimulated NK cells, co‐cultured with K562 cells (Bottom). (**C**) CD69+, CD25+ or CD38+ cells were determined in vehicle (control) or anti‐CD3/CD28‐stimulated CD4^+^ T‐cells. At least one thousand events were acquired for both NK and CD4^+^ T‐cell gates.

###### 

Click here for additional data file.

###### 

**Figure S3.** Evaluation of NK cell effector functions in CD56 dim and bright populations. (**A**) PBMCs from healthy and HIV/HCV‐coinfected individuals with METAVIR F0/F1 or F4 scores were incubated with cRPMI (basal) or K562 cells (+K562). Fold change induction in CD107a expression (+K562/basal) was evaluated in CD56^dim^ and CD56^bright^ cell subsets. (**B** and **C**) For cytokine expression, PBMCs cells were pretreated with conditioned medium from CD4^+^ T‐lymphocytes, and subsequently exposed to K562 cells. Frequencies of IFN‐γ **(B)** and TNF‐α‐positive cells (**C**) were determined in CD56^dim^ and CD56^bright^ cell subsets. Statistical analysis was performed using Kruskal‐Wallis followed by Dunn′s multiple‐comparison.
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Click here for additional data file.
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**Table S1.** Fluorochrome‐conjugated antibody panels.

**Table S2.** Differences in NK and CD4^+^ T‐cell phenotypic and functional markers according gender.
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Click here for additional data file.
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